NCT02347423View on ClinicalTrials.gov

3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

824

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 26, 2015

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI

BIOLOGICAL

IPV Vaccine SSI

Trial Locations (1)

Unknown

Hospital Maternidad Nuestra de la Altagracia, Santo Domingo

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Quintiles, Inc.

INDUSTRY

collaborator

Larix A/S

INDUSTRY

lead

Statens Serum Institut

OTHER

NCT02347423 - 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants | Biotech Hunter | Biotech Hunter